Your browser doesn't support javascript.
loading
Advanced glycation end products and cognitive impairment in schizophrenia.
Kobori, Akiko; Miyashita, Mitsuhiro; Miyano, Yasuhiro; Suzuki, Kazuhiro; Toriumi, Kazuya; Niizato, Kazuhiro; Oshima, Kenichi; Imai, Atsushi; Nagase, Yukihiro; Yoshikawa, Akane; Horiuchi, Yasue; Yamasaki, Syudo; Nishida, Atsushi; Usami, Satoshi; Takizawa, Shunya; Itokawa, Masanari; Arai, Heii; Arai, Makoto.
Affiliation
  • Kobori A; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Miyashita M; Department of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
  • Miyano Y; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Suzuki K; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
  • Toriumi K; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan.
  • Niizato K; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Oshima K; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
  • Imai A; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Nagase Y; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan.
  • Yoshikawa A; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Horiuchi Y; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
  • Yamasaki S; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
  • Nishida A; Department of Psychiatry, Tokyo Metropolitan Matsuzawa Hospital, Setagaya-ku, Tokyo, Japan.
  • Usami S; Department of Psychiatry, Takatsuki Hospital, Hachioji, Tokyo, Japan.
  • Takizawa S; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Itokawa M; Department of Psychiatry and Behavioral Sciences, Schizophrenia Research Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Arai H; Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
  • Arai M; Research Center for Social Science & Medicine, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan.
PLoS One ; 16(5): e0251283, 2021.
Article in En | MEDLINE | ID: mdl-34038433
ABSTRACT
Advanced glycation end products play a key role in the pathophysiology of schizophrenia. Cognitive impairment is one of the central features of schizophrenia; however, the association between advanced glycation end products and cognitive impairment remains unknown. This study investigated whether advanced glycation end products affect the cognitive domain in patients with schizophrenia. A total of 58 patients with chronic schizophrenia were included in this cross-sectional study. Plasma advanced glycation end products were measured using high-performance liquid chromatography (HPLC). Neuropsychological and cognitive functions were assessed using the Wechsler Adult Intelligence Scale, Third Version, and the Wisconsin Card Sorting Test Keio-FS version. Multiple regression analysis adjusted for age, sex, body mass index, educational years, daily dose of antipsychotics, and psychotic symptoms revealed that processing speed was significantly associated with plasma pentosidine, a representative advanced glycation end product (standardized ß = -0.425; p = 0.009). Processing speed is the cognitive domain affected by advanced glycation end products. Considering preceding evidence that impaired processing speed is related to poor functional outcome, interventions targeted at reducing advanced glycation end products may contribute to promoting recovery of patients with schizophrenia as well as cognitive function improvement.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Glycation End Products, Advanced / Cognitive Dysfunction Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia / Glycation End Products, Advanced / Cognitive Dysfunction Type of study: Observational_studies / Prevalence_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country: Japan